Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8829328 | 0.89 | TDP1 (0.49) | TDP1MAPK1POLBALDH1A1 | |
| SCHEMBL3047380 | 0.88 | TDP1 (0.45) | TDP1MAPK1POLB | |
| SCHEMBL3054750 | 0.88 | TDP1 (0.45) | TDP1MAPK1POLB | |
| SCHEMBL4656048 | 0.87 | TDP1 (0.47) | TDP1MAPK1POLB | |
| SCHEMBL7037710 | 0.87 | TDP1 (0.47) | TDP1MAPK1POLB | |
| SCHEMBL1290131 | 0.87 | TDP1 (0.47) | TDP1MAPK1POLB | |
| SCHEMBL2527102 | 0.81 | TDP1 (0.47) | TDP1 | |
| SCHEMBL2527099 | 0.81 | TDP1 (0.47) | TDP1 | |
| SCHEMBL4604940 | 0.77 | TDP1 (0.50) | TDP1MAPK1POLBUSP2ALDH1A1 | |
| SCHEMBL4605823 | 0.76 | TDP1 (0.49) | TDP1MAPK1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1572708-B1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1572707-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572708-A1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052903-A1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SLC5A2, SLC5A1, UGGT1 | TDP1 3772/4885MAPK1 728/4885POLB 4570/4885 |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | UGGT1, SLC5A2, SLC5A1 | TDP1 4085/4885MAPK1 1155/4885POLB 4398/4885 |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A1, UGGT1, SLC5A2 | TDP1 3804/4885MAPK1 783/4885POLB 4474/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | TDP1 3772/4885MAPK1 728/4885POLB 4570/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | TDP1 4561/4885MAPK1 226/4885POLB 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.